SAH-SOS1A TFA|西域试剂

SAH-SOS1A TFA,99.16%

产品编号：Bellancom-P2265A| 分子式：C₁₀₂H₁₆₀N₂₇F₃O₃₀| 分子量：2301.55

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P2265A		￥4200.00	杭州北京（现货）
Bellancom-P2265A		￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SAH-SOS1A TFA

产品介绍

SAH-SOS1A TFA 是一种基于肽的 SOS1/KRAS 蛋白相互作用抑制剂。SAH-SOS1A TFA 以纳摩尔亲和力 (EC₅₀=106-175 nM) 与野生型和突变型 KRAS (G12D, G12V, G12C, G12S, Q61H) 结合，直接和独立地阻断核苷酸结合。SAH-SOS1A TFA 损害 KRAS 驱动的癌细胞活力，并通过阻断 KRAS 下游 ERK-MAPK 磷酸化信号级联的机制发挥作用。

生物活性

SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.

体外研究

SAH-SOS1A TFA (0.625-40 μM; 24 hours) dose-responsively impairs the viability of cancer cells bearing G12D, G12C, G12V, G12S, G13D, and Q61H mutations with IC50 values in the 5- to 15-μM range. Cancer cells expressing wild-type KRAS, such as HeLa and Colo320-HSR cells, are similarly affected.
SAH-SOS1A TFA (5-40 μM; 4 hours) dose-responsively inhibits MEK1/2, ERK1/2, and AKT phosphorylation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Panc 10.05 cells bearing the KRAS G12D mutation
Concentration:	0.625-40 μM
Incubation Time:	24 hours
Result:	Dose-responsively impaired the viability of cancer cells bearing KRAS G12D.

Western Blot Analysis

Cell Line:	Panc 10.05 cells
Concentration:	5-40 μM
Incubation Time:	Indicated doses for 4 h, followed by 15-min stimulation with EGF
Result:	Dose-responsively inhibited MEK1/2, ERK1/2, and AKT phosphorylation.

体内研究
(In Vivo)

SAH-SOS1A (0.2 μL of 10 mM solution; injection; 48 hours; abdomens of D. melanogaster Ras85D^V12/ActinGS) treatment notably decreases the phosphorylation state of ERK1/2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SAH-SOS1A (0.2 μL of 10 mM solution; injection; 48 hours; abdomens of D. melanogaster Ras85D^V12/ActinGS) treatment notably decreases the phosphorylation state of ERK1/2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SAH-SOS1A (0.2 μL of 10 mM solution; injection; 48 hours; abdomens of D. melanogaster Ras85D^V12/ActinGS) treatment notably decreases the phosphorylation state of ERK1/2.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : 33.33 mg/mL (14.48 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.4345 mL	2.1724 mL	4.3449 mL
5 mM	0.0869 mL	0.4345 mL	0.8690 mL
10 mM	0.0434 mL	0.2172 mL	0.4345 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen